Robert Byram
Family · New Orleans, LANPI 1356528616
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,792 of the $9,788 with a category attached, or 79.6%. 48 manufacturers reported payments, led by Incyte Corporation at 29.2% of the total. Reporting peaked in 2023 at $4,523 and has fallen 67.3% since, to $1,478 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $34.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$3K
- Sobi, Inc$540
- Novartis$521
- Astellas Pharma US Inc$415
- Bristol Myers Squibb$396
- Sanofi$370
- plus $5K from 42 others
Across 2 payments — averaging $19,436 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$39K
What the payments were for
- Consulting fees$1,15512%
- Travel & lodging$2142%
- Food & beverage$7,79280%
- Education$6286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,788 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 182 | $4,162,771 |
| RezurockBelumosudil Mesylate | 56 | $992,560 |
| Lenalidomide | 50 | $873,719 |
| JakafiRuxolitinib Phosphate | 35 | $602,523 |
| PomalystPomalidomide | 27 | $600,510 |
| BrukinsaZanubrutinib | 48 | $516,434 |
| ImbruvicaIbrutinib | 32 | $468,512 |
| VenclextaVenetoclax | 30 | $270,219 |
| DopteletAvatrombopag Maleate | 12 | $219,493 |
| BesremiRopeginterferon Alfa-2b-Njft | 11 | $167,078 |
| EliquisApixaban | 30 | $25,567 |
| Voriconazole | 13 | $5,811 |
| Acyclovir | 194 | $2,330 |
| Colesevelam Hcl | 16 | $1,962 |
| Tacrolimus | 33 | $1,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $396 | $4,162,771182 claims |
| Sanofi-aventis U.S. LLCRezurock | $80 | $992,56056 claims |
| Incyte CorporationJakafi | $2,860 | $602,52335 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $321 | $600,51027 claims |
| Beigene USA, Inc.Brukinsa | $68 | $516,43448 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $47 | $468,51232 claims |
| AbbVieVenclexta | $94 | $270,21930 claims |
| Pharmaessentia USA CorporationBesremi | $160 | $167,07811 claims |
| PfizerEliquis | $61 | $25,56730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in New Orleans
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Amy SchmittNew Orleans$48K
- Eric BabineauxNew Orleans$32K
- Cherie AlbroNew Orleans$29K
- Aimee ScroggsNew Orleans$20K
- Kelly BaquetNew Orleans$18K
- Lori LemoineNew Orleans$17K
- Jennifer GreenheckNew Orleans$15K
- Joseph DefraitesNew Orleans$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.